Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2014-10-21

AUTHORS

Paul M. McKie, John C. Burnett

ABSTRACT

The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF. More... »

PAGES

7-14

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s11897-014-0235-3

DOI

http://dx.doi.org/10.1007/s11897-014-0235-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031193038

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/25331110


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin Receptor Antagonists", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin-Converting Enzyme Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Heart Failure", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Natriuretic Peptides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neprilysin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protease Inhibitors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "McKie", 
        "givenName": "Paul M.", 
        "id": "sg:person.01271304603.22", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA", 
          "id": "http://www.grid.ac/institutes/grid.66875.3a", 
          "name": [
            "Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burnett", 
        "givenName": "John C.", 
        "id": "sg:person.01001266776.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/978-3-540-68964-5_15", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002318921", 
          "https://doi.org/10.1007/978-3-540-68964-5_15"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.328", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035621233", 
          "https://doi.org/10.1038/ng.328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/378065a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015449350", 
          "https://doi.org/10.1038/378065a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11897-010-0016-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022530445", 
          "https://doi.org/10.1007/s11897-010-0016-6"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/cc10606", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018473584", 
          "https://doi.org/10.1186/cc10606"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002280050196", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020503072", 
          "https://doi.org/10.1007/s002280050196"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11906-001-0102-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053694779", 
          "https://doi.org/10.1007/s11906-001-0102-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00109-010-0641-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045002962", 
          "https://doi.org/10.1007/s00109-010-0641-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/s0009-9236(98)90075-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021742259", 
          "https://doi.org/10.1016/s0009-9236(98)90075-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2014-10-21", 
    "datePublishedReg": "2014-10-21", 
    "description": "The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of\u00a0chronic augmentation of the NPS in\u00a0symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s11897-014-0235-3", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1033049", 
        "issn": [
          "1546-9530", 
          "1546-9549"
        ], 
        "name": "Current Heart Failure Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "natriuretic peptide system", 
      "heart failure", 
      "chronic augmentation", 
      "progression of HF", 
      "symptomatic heart failure", 
      "cardiorenal homeostasis", 
      "subsequent morbidity", 
      "beneficial remodeling", 
      "therapeutic augmentation", 
      "neurohumoral inhibition", 
      "therapeutic opportunities", 
      "therapeutic development", 
      "peptide system", 
      "augmentation", 
      "current manuscript", 
      "early stages", 
      "vasorelaxation", 
      "morbidity", 
      "failure", 
      "pathophysiology", 
      "mortality", 
      "important role", 
      "progression", 
      "rationale", 
      "dysregulation", 
      "remodeling", 
      "homeostasis", 
      "inhibition", 
      "health", 
      "current efforts", 
      "role", 
      "stage", 
      "development", 
      "manuscript", 
      "efforts", 
      "system augmentation", 
      "opportunities", 
      "system"
    ], 
    "name": "Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure", 
    "pagination": "7-14", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031193038"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s11897-014-0235-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "25331110"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s11897-014-0235-3", 
      "https://app.dimensions.ai/details/publication/pub.1031193038"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_626.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s11897-014-0235-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s11897-014-0235-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s11897-014-0235-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s11897-014-0235-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s11897-014-0235-3'


 

This table displays all metadata directly associated to this object as RDF triples.

175 TRIPLES      22 PREDICATES      81 URIs      64 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s11897-014-0235-3 schema:about N1b19d95ba3d04e91a939fc725f40af2d
2 N43b9e8eef9e74998942950c3b6821c27
3 N52365c4704c944aa902c79585280efd2
4 Na1b9e4d7c8b1471e9ae4cf4380f33fea
5 Nbcfc7b7737a54899bd906a42692ead02
6 Nc5c4cb2e80444c8b86922b28bba16fe6
7 Ne4a23e0645ef49798893c23541260f36
8 Nf0ac4348d5a741fd8eaecfd201d17ccd
9 anzsrc-for:11
10 anzsrc-for:1102
11 schema:author Nc97959e88ae745ef804ffeb3b2fe22b2
12 schema:citation sg:pub.10.1007/978-3-540-68964-5_15
13 sg:pub.10.1007/s00109-010-0641-2
14 sg:pub.10.1007/s002280050196
15 sg:pub.10.1007/s11897-010-0016-6
16 sg:pub.10.1007/s11906-001-0102-y
17 sg:pub.10.1016/s0009-9236(98)90075-3
18 sg:pub.10.1038/378065a0
19 sg:pub.10.1038/ng.328
20 sg:pub.10.1186/cc10606
21 schema:datePublished 2014-10-21
22 schema:datePublishedReg 2014-10-21
23 schema:description The natriuretic peptide system (NPS) is intimately involved in cardiorenal homeostasis in health, and dysregulation of the NPS plays an important role in the pathophysiology of heart failure (HF). Indeed, the diuretic, vasorelaxation, beneficial remodeling, and potent neurohumoral inhibition of the NPS support the therapeutic development of chronic augmentation of the NPS in symptomatic HF. Further, chronic augmentation of the protective NPS and in early stages of HF may ultimately prevent the progression of HF and reduced subsequent morbidity and mortality. In the current manuscript, we review the rationale for as well as previous and current efforts aimed at chronic therapeutic augmentation of the NPS in HF.
24 schema:genre article
25 schema:inLanguage en
26 schema:isAccessibleForFree false
27 schema:isPartOf N5487b661f31c4980bf76a2e0b8b31d2c
28 N60865a7704d74108a21b413a838070d3
29 sg:journal.1033049
30 schema:keywords augmentation
31 beneficial remodeling
32 cardiorenal homeostasis
33 chronic augmentation
34 current efforts
35 current manuscript
36 development
37 dysregulation
38 early stages
39 efforts
40 failure
41 health
42 heart failure
43 homeostasis
44 important role
45 inhibition
46 manuscript
47 morbidity
48 mortality
49 natriuretic peptide system
50 neurohumoral inhibition
51 opportunities
52 pathophysiology
53 peptide system
54 progression
55 progression of HF
56 rationale
57 remodeling
58 role
59 stage
60 subsequent morbidity
61 symptomatic heart failure
62 system
63 system augmentation
64 therapeutic augmentation
65 therapeutic development
66 therapeutic opportunities
67 vasorelaxation
68 schema:name Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure
69 schema:pagination 7-14
70 schema:productId N4584224714854f7aabcdc89d96a0a77b
71 Ndf051e8ab7d7462c9faf2072fb290706
72 Ne650cc8f7f504e80b60fe5f511e9150a
73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031193038
74 https://doi.org/10.1007/s11897-014-0235-3
75 schema:sdDatePublished 2022-06-01T22:11
76 schema:sdLicense https://scigraph.springernature.com/explorer/license/
77 schema:sdPublisher N5a31748ec0ca41b89cf8f791e09904ef
78 schema:url https://doi.org/10.1007/s11897-014-0235-3
79 sgo:license sg:explorer/license/
80 sgo:sdDataset articles
81 rdf:type schema:ScholarlyArticle
82 N1b19d95ba3d04e91a939fc725f40af2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Humans
84 rdf:type schema:DefinedTerm
85 N43b9e8eef9e74998942950c3b6821c27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Neprilysin
87 rdf:type schema:DefinedTerm
88 N4584224714854f7aabcdc89d96a0a77b schema:name dimensions_id
89 schema:value pub.1031193038
90 rdf:type schema:PropertyValue
91 N52365c4704c944aa902c79585280efd2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Angiotensin-Converting Enzyme Inhibitors
93 rdf:type schema:DefinedTerm
94 N5487b661f31c4980bf76a2e0b8b31d2c schema:issueNumber 1
95 rdf:type schema:PublicationIssue
96 N5a31748ec0ca41b89cf8f791e09904ef schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N60865a7704d74108a21b413a838070d3 schema:volumeNumber 12
99 rdf:type schema:PublicationVolume
100 Na1b9e4d7c8b1471e9ae4cf4380f33fea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Drug Therapy, Combination
102 rdf:type schema:DefinedTerm
103 Nbcfc7b7737a54899bd906a42692ead02 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Heart Failure
105 rdf:type schema:DefinedTerm
106 Nc5c4cb2e80444c8b86922b28bba16fe6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Angiotensin Receptor Antagonists
108 rdf:type schema:DefinedTerm
109 Nc97959e88ae745ef804ffeb3b2fe22b2 rdf:first sg:person.01271304603.22
110 rdf:rest Nf159723810bf4b26994d78a973a5a187
111 Ndf051e8ab7d7462c9faf2072fb290706 schema:name pubmed_id
112 schema:value 25331110
113 rdf:type schema:PropertyValue
114 Ne4a23e0645ef49798893c23541260f36 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Natriuretic Peptides
116 rdf:type schema:DefinedTerm
117 Ne650cc8f7f504e80b60fe5f511e9150a schema:name doi
118 schema:value 10.1007/s11897-014-0235-3
119 rdf:type schema:PropertyValue
120 Nf0ac4348d5a741fd8eaecfd201d17ccd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Protease Inhibitors
122 rdf:type schema:DefinedTerm
123 Nf159723810bf4b26994d78a973a5a187 rdf:first sg:person.01001266776.01
124 rdf:rest rdf:nil
125 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
126 schema:name Medical and Health Sciences
127 rdf:type schema:DefinedTerm
128 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
129 schema:name Cardiorespiratory Medicine and Haematology
130 rdf:type schema:DefinedTerm
131 sg:journal.1033049 schema:issn 1546-9530
132 1546-9549
133 schema:name Current Heart Failure Reports
134 schema:publisher Springer Nature
135 rdf:type schema:Periodical
136 sg:person.01001266776.01 schema:affiliation grid-institutes:grid.66875.3a
137 schema:familyName Burnett
138 schema:givenName John C.
139 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01001266776.01
140 rdf:type schema:Person
141 sg:person.01271304603.22 schema:affiliation grid-institutes:grid.66875.3a
142 schema:familyName McKie
143 schema:givenName Paul M.
144 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271304603.22
145 rdf:type schema:Person
146 sg:pub.10.1007/978-3-540-68964-5_15 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002318921
147 https://doi.org/10.1007/978-3-540-68964-5_15
148 rdf:type schema:CreativeWork
149 sg:pub.10.1007/s00109-010-0641-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045002962
150 https://doi.org/10.1007/s00109-010-0641-2
151 rdf:type schema:CreativeWork
152 sg:pub.10.1007/s002280050196 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020503072
153 https://doi.org/10.1007/s002280050196
154 rdf:type schema:CreativeWork
155 sg:pub.10.1007/s11897-010-0016-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022530445
156 https://doi.org/10.1007/s11897-010-0016-6
157 rdf:type schema:CreativeWork
158 sg:pub.10.1007/s11906-001-0102-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1053694779
159 https://doi.org/10.1007/s11906-001-0102-y
160 rdf:type schema:CreativeWork
161 sg:pub.10.1016/s0009-9236(98)90075-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021742259
162 https://doi.org/10.1016/s0009-9236(98)90075-3
163 rdf:type schema:CreativeWork
164 sg:pub.10.1038/378065a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015449350
165 https://doi.org/10.1038/378065a0
166 rdf:type schema:CreativeWork
167 sg:pub.10.1038/ng.328 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035621233
168 https://doi.org/10.1038/ng.328
169 rdf:type schema:CreativeWork
170 sg:pub.10.1186/cc10606 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018473584
171 https://doi.org/10.1186/cc10606
172 rdf:type schema:CreativeWork
173 grid-institutes:grid.66875.3a schema:alternateName Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA
174 schema:name Cardiorenal Research Laboratory, Division of Cardiovascular Diseases, Mayo Clinic and Foundation, 200 First Street SW, 55905, Rochester, MN, USA
175 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...